According to Guangyuan Capital, Beijing Huaguan Biotechnology Co., Ltd. recently completed a Series C financing round worth hundreds of millions of RMB. This round of funding was jointly invested by SoftBank Innovation Fund, Shunxi Fund, Changzhou Qihang Synthetic Biology Venture Capital Fund, Guotou Chuangyi, Yangtze River Capital, and other institutions, with Guangyuan Capital serving as the exclusive financial advisor. The funds raised will be primarily used for new product research and development, expansion of production facilities in the pharmaceutical and health sectors, and the construction of innovative collaboration platforms.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Huaguan Biology completes hundreds of millions of yuan in Series C funding
According to Guangyuan Capital, Beijing Huaguan Biotechnology Co., Ltd. recently completed a Series C financing round worth hundreds of millions of RMB. This round of funding was jointly invested by SoftBank Innovation Fund, Shunxi Fund, Changzhou Qihang Synthetic Biology Venture Capital Fund, Guotou Chuangyi, Yangtze River Capital, and other institutions, with Guangyuan Capital serving as the exclusive financial advisor. The funds raised will be primarily used for new product research and development, expansion of production facilities in the pharmaceutical and health sectors, and the construction of innovative collaboration platforms.